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The central nervous system is characterized by a high content of sphingolipids and 
by a high diversity in terms of different structures. Stage- and cell-specific sphingolipid 
metabolism and expression are crucial for brain development and maintenance 
toward adult age. On the other hand, deep dysregulation of sphingolipid metabolism, 
leading to altered sphingolipid pattern, is associated with the majority of neurological 
and neurodegenerative diseases, even those totally lacking a common etiological 
background. Thus, sphingolipid metabolism has always been regarded as a promising 
pharmacological target for the treatment of brain disorders. However, any therapeutic 
hypothesis applied to complex amphipathic sphingolipids, components of cellular 
membranes, has so far failed probably because of the high regional complexity and 
specificity of the different biological roles of these structures. Simpler sphingosine-
based lipids, including ceramide and sphingosine 1-phosphate, are important regulators 
of brain homeostasis, and, thanks to the relative simplicity of their metabolic network, 
they seem a feasible druggable target for the treatment of brain diseases. The enzymes 
involved in the control of the levels of bioactive sphingoids, as well as the receptors 
engaged by these molecules, have increasingly allured pharmacologists and clinicians, 
and eventually fingolimod, a functional antagonist of sphingosine 1-phosphate receptors 
with immunomodulatory properties, was approved for the therapy of relapsing–remitting 
multiple sclerosis. Considering the importance of neuroinflammation in many other brain 
diseases, we would expect an extension of the use of such analogs for the treatment of 
other ailments in the future. Nevertheless, many aspects other than neuroinflammation 
are regulated by bioactive sphingoids in healthy brain and dysregulated in brain disease. 
In this review, we are addressing the multifaceted possibility to address the metabolism 
and biology of bioactive sphingosine 1-phosphate as novel targets for the development 
of therapeutic paradigms and the discovery of new drugs.
Keywords: sphingosine 1-phosphate, fingolimod, FTY720, sphingosine 1-phosphate receptors, sphingosine 
kinase, sphingosine 1-phosphate phosphatase, sphingosine 1-phosphate lyase
Targeting Sphingosine 1-Phosphate in Brain DiseasesGrassi et al.
2 July 2019 | Volume 10 | Article 807Frontiers in Pharmacology | www.frontiersin.org
INTRODUCTION
Sphingolipids are a wide group of eukaryotic cellular lipids, 
whose common structural feature is the presence of a 2-amino-
1,3-dihydroxy-octadec-4-ene, trivially known as “sphingosine” 
(Roisen et al., 1981) (2S,3R,4E). In addition to the C18 molecular 
species, which is usually the most abundant in complex 
sphingolipids in mammals, structures with shorter and longer 
alkyl chains have been identified as minor components in 
different biological samples, and complex glycosphingolipids 
containing sphingosine with 20 carbon atoms are relatively 
abundant in mammalian brain and in cultured neurons (Sonnino 
and Chigorno, 2000). Usually, the term “sphingolipids” is referred 
to as the complex amphipathic lipids of this family, whose 
hydrophobic moiety is represented by ceramide. In ceramide, the 
sphingosine is linked via an amide bond with a fatty acid, whose 
structure can greatly vary for its acyl chain length and the presence 
of double bonds. Ceramide is the precursor for the biosynthesis 
of amphipathic sphingolipids, characterized by the presence of 
a polar head group of different nature and chemical complexity 
linked to the hydroxyl group at the position 1 of ceramide. 
Phosphocholine is the hydrophilic head group of sphingomyelin 
(SM) (the only membrane phosphosphingolipid present in 
mammals). On the other hand, a phosphate group linked to 
the hydroxyl group is present in sphingosine 1-phosphate and 
ceramide-1-phosphate. In glycosphingolipids, the polar head 
group is represented by a single sugar (in cerebrosides) or by 
an oligosaccharide chain that can be relatively complex, as 
in polysialogangliosides. In addition to glycosphingolipids 
containing neutral sugars, two families of glycosphingolipids in 
eukaryotes are characterized by the presence of acidic residues 
in the oligosaccharide chain: sulfatides, containing one or more 
sulfate groups, bond via O-glycosidic linkage on a glucose or 
galactose residue; and gangliosides, hallmarked by the presence 
of one or more sialic acids, a family of sugars characterized by the 
presence of a carboxyl group (Schauer, 1982) (Figure 1).
Sphingolipids are in general minor cell membrane 
components. Most glycosphingolipids do not form bilayers 
spontaneously in aqueous environment; however, they can 
accommodate in the glycerophospholipid bilayer, thanks to their 
hydrophobic moiety, ceramide. Sphingolipids are ubiquitous 
components of mammalian cell membranes; however, their 
distribution is highly organ- and tissue-specific. Indeed, in some 
cases, imaging mass spectrometry is also revealing a cell-specific 
distribution. For example, neuron subpopulations located in 
very close proximity can bear dramatic differences in their 
sphingolipid repertoire (Hirano-Sakamaki et al., 2015; Sugiyama 
and Setou, 2018). The nervous system is the mammalian tissue 
with the highest concentration in sphingolipids. Within the 
nervous system, SM is highly expressed in oligodendrocytes 
and in neurons. Galactosylceramide and its sulfated derivative, 
3-O-sulfogalactosyceramide (sulfatide) are highly expressed 
in myelin, whereas polysialogangliosides of the ganglio series 
are abundant in neurons (we showed that ganglio series 
gangliosides represent about 5% of total amphipathic lipids in 
cultured cerebellar granule cells; Prinetti et al., 2000). Even if 
minor components in average cell membranes, sphingolipids 
are highly concentrated in the plasma membrane and 
asymmetrically distributed in the exoplasmic leaflet. Moreover, 
sphingolipids are not homogeneously distributed at the cell 
surface, but they tend to cluster, forming sphingolipid-rich 
membrane areas or “domains” (Sonnino et al., 2007; Sonnino 
et al., 2014); thus, their local concentration within a specific 
membrane microenvironment can be very high. Plasma 
membrane sphingolipids, and in particular glycosphingolipids 
(Sonnino and Prinetti, 2010), do exert important biological 
functions, affecting the properties of plasma membrane-
associated proteins (e.g., growth factor receptors, adhesion 
molecules) via direct interactions or via the modulation of 
the protein membrane microenvironment (Loberto et al., 
2005; Rivaroli et al., 2007). Glycosphingolipid-mediated 
interactions can also involve ligands occurring on adjacent 
cells (trans interactions). For example, the trans interaction 
between sulfatide and galactosylceramide clustered in distinct 
membrane microdomains at the juxtaposed membranes of 
myelin wrap plays a relevant role in the proper maintenance of 
mature myelin function, as well as in myelin formation (Boggs 
et al., 2010). On the axonal side, the polysialogangliosides GD1a 
and GT1b organized in clusters do engage trans interactions 
with the glycoprotein MAG on the innermost myelin sheath 
(Schnaar and Lopez, 2009), contributing to long-term axon–
myelin stability.
Ceramide, synthesized in the endoplasmic reticulum (ER), 
is the common precursor for the biosynthesis of SM and 
glycosphingolipids (Figure 2). In turn, degradation of SM 
and glycosphingolipids at the lysosomal level or in another 
subcellular localization can yield ceramide. Lysosomal 
ceramide is the key intermediate of complete catabolism of 
complex sphingolipids. Sphingosine, generated by ceramide 
hydrolysis, can be phosphorylated from two known sphingosine 
kinases (SK1 and SK2) to produce sphingosine 1-phosphate 
(S1P) (Figure 1), which is irreversibly cleaved by an S1P 
lyase, yielding phosphoethanolamine and a fatty aldehyde 
(Figure 2). For decades, ceramide, sphingosine, and S1P have 
been regarded solely as intermediates in complex sphingolipid 
metabolism. However, from the end of the 1980s, a number 
of papers appeared, describing the effects of these molecules 
on a plethora of cellular targets, implying their involvement 
in several biological processes. For these relatively simple 
sphingosine-based molecules, the term “bioactive sphingoids” 
has been coined.
Abbreviations: 3-kdhSo, 3-ketodihydrosphingosine; AD, Alzheimer’s 
disease; APP, amyloid precursor protein; BBB, blood brain barrier; CerS, 
ceramide synthases; CDase, ceramidase; CNS, central nervous system; 
DES1, dihydroceramide desaturase 1; dhCer, dihydroceramide; dhSo, 
dihydrosphingosine; EAE, experimental autoimmune encephalomyelitis; 
GCase, glycosidases; HD, Huntington disease; HDAC(s), histone deacetylase(s); 
KDSR, 3-ketodihydrosphingosine reductase; LPS, lipopolysaccharide; MS, 
multiple sclerosis; NF-κB, nuclear factor κB; PD, Parkinson’s disease; PI3K, 
phosphoinositide 3-kinase; PS1, presenilin-1; ROS, reactive oxygen species; 
S1P, sphingosine 1-phosphate; S1P1-5, S1P receptor 1 to 5; SGPL1, sphingosine 
1-phosphate lyase; SK1, sphingosine kinase 1; SK2, sphingosine kinase 2; SM, 
sphingomyelin; SMase, sphingomyelinase; SPP1, S1P phosphatase; SPT, serine 
palmitoyltransferase; RR-MS, relapsing–remitting multiple sclerosis; SP-MS, 
secondary progressive multiple sclerosis.
Targeting Sphingosine 1-Phosphate in Brain DiseasesGrassi et al.
3 July 2019 | Volume 10 | Article 807Frontiers in Pharmacology | www.frontiersin.org
Stimulus-mediated SM hydrolysis by sphingomyelinases 
(SMases) (Hannun, 1994) was described as the main source of 
bioactive ceramide. The production of bioactive ceramide is not 
necessarily a lysosomal event because SMases are present at the 
plasma membrane or can be recruited to it from intracellular 
sites as a consequence of different stimuli (Levade and Jaffrezou, 
1999; Goni and Alonso, 2002). Ceramide, acting on specific 
cellular targets (including several signaling protein kinases and 
phosphoprotein phosphatases) or determining the reorganization 
of plasma membrane signaling platforms (Zhang et al., 2009), 
regulates several cellular events, most notably programmed 
cell death with important consequences in cancer, including 
inflammation, bacterial infection, and signaling pathways 
related to Alzheimer’s disease (AD) and other neurodegenerative 
and neurological disorders (Van Echten-Deckert and Walter, 
2012; Czubowicz et al., 2019). On the other hand, ceramide 
can be phosphorylated by a specific ceramide kinase yielding 
ceramide 1-phosphate, another bioactive molecule acting on 
its own cellular targets (Presa et al., 2016). Ceramide hydrolysis 
by various ceramidases negatively regulates ceramide levels; 
however, it fuels the production of S1P by providing sphingosine 
as a substrate for sphingosine kinases. As already mentioned, 
S1P derived from the catabolism of ceramide and more complex 
sphingolipids is an important biologically active mediator 
involved in diverse signal transduction pathways that regulate 
many different cell functions, in some cases, with effects opposed 
to those of ceramide. Considering the high numbers of enzymes, 
transporters, cellular targets, and receptors involved in the 
regulation of the cellular levels of bioactive sphingoids, and in 
their cellular actions, they do represent an intriguing druggable 
target for many pathologies.
SPHINGOSINE 1-PHOSPHATE 
METABOLISM AND SIGNALING
As mentioned above, ceramide-derived sphingosine can either be 
recycled for the resynthesis of sphingolipids or be phosphorylated 
at C1 with the generation of S1P by two isoforms of sphingosine 
kinase, sphingosine kinase 1 (SK1), and sphingosine kinase 2 
(SK2). S1P can be metabolized through irreversible cleavage 
by the S1P lyase enzyme (Serra and Saba, 2010) (SGPL1) to a 
fatty aldehyde (hexadecenal if starting from the most common 
C18 sphingosine) and phosphoethanolamine; alternatively, S1P 
can also be dephosphorylated back to sphingosine through a 
reaction that is catalyzed by lipid phosphatase or S1P-specific 
phosphatases (Le Stunff et al., 2002; Le Stunff et al., 2007; Pyne 
et al., 2009; Giussani et al., 2014).
S1P is released from cells in the extracellular milieu through 
specific transporters [spinster homolog 2 (Spns2) or ABC 
transporters], then from the extracellular milieu, S1P binds to 
a family of plasma membrane G protein-coupled receptors, the 
S1P receptors (S1P1–S1P5) (Giussani et al., 2014; Pyne et al., 
2016), triggering different biological responses (Figure 3). On 
the other hand, S1P generated intracellularly by the action of 
SK2 can engage to various targets, including HDAC-1/2 (Hait 
FIGURE 1 | Chemical structures of sphingosine, ceramide, sphingosine 1-phosphate, galactosylceramide, sphingomyelin, and monosialoganglioside GM1.
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et al., 2009), human telomerase reverse transcriptase (hTERT) 
(Panneer Selvam et al., 2015), and prohibitin 2 (Strub et al., 
2011). Thus, the activity of SK2 seems relevant for diverse and 
crucial biological events, including epigenetic regulation, aging, 
and mitochondrial respiratory complex assembly (Pyne et al., 
2017) (Figure 3).
It is now known that S1P metabolism is tightly regulated. 
In particular, new pieces of evidence indicating specific 
roles for SK1 and SK2 in different diseases, including cancer, 
cardiovascular system and central nervous system (CNS) 
affections, inflammation, and diabetes, have been recently 
published (Pyne et al., 2016; Cattaneo et al., 2018). In particular, 
the role of S1P/SK2 pathway in regulating the survival of 
the dopaminergic neurons has emerged, suggesting that 
dysregulation of this pathway might be relevant to the clinical 
development of Parkinson’s disease (PD); in addition, a role for 
SK1 and SK2 has also been suggested in the onset of AD (Pyne 
et al., 2016). Moreover, Hagen et al., (2009) demonstrated 
that there is an additional aspect of S1P generated by SK2 that 
may exert a neurotoxic effect, inducing apoptosis in lyase-
deficient neurons.
Moreover, the involvement of S1P/S1P lyase in cystic fibrosis 
pathology is supported by the evidence that in a murine cystic 
fibrosis model, treatment with a specific SGPL1 inhibitor 
is able to alter S1P metabolism and results in a reduction of 
the lung inflammatory response to Pseudomonas aeruginosa 
(Veltman et al., 2016).
S1P is a positive regulator of cellular survival, proliferation, 
and motility in glial cells (Bassi et al., 2006). In particular, it 
has been shown that S1P is able to mediate calcium signaling 
in cultured cerebellar astrocytes, whereas it failed to trigger any 
calcium-mediated response in differentiated cerebellar neurons. 
This effect could be important for neuron–glia communication 
in the cerebellum (Giussani et al., 2007).
FIGURE 2 | Subcellular compartmentalization of sphingolipid metabolism. The endoplasmic reticulum (ER) is the subcellular site where the de novo ceramide 
(Cer) synthesis occurs (A). Here, the synthesis of the sphingoid bases (sphingosine) starts with the condensation of palmitoyl-CoA and serine, catalyzed by serine 
palmitoyltransferase (SPT). The product of this reaction is 3-ketodihydrosphingosine (3-kdhSo), which is later reduced to dihydrosphingosine (dhSo) via the action of 
3-ketodihydrosphingosine reductase (KDSR). Then, dhSo is acylated generating dihydroceramide (dhCer). In humans, this reaction occurs through the activities of 
six different ceramide synthases (CerS). Dihydroceramide is then unsaturated to ceramide by the enzyme dihydroceramide desaturase 1 (DES1). At ER level, Cer is 
either transformed into GalCer (●) by CGalT (B) or delivered by ceramide transport protein (CERT) (C) or through vesicular transport (D) to the Golgi apparatus for 
the synthesis of sphingomyelin (SM ●) by SMS1 and glucosylceramide (GlcCer ●) by GCS (E). At the Golgi, GlcCer is transformed into lactosylceramide (LacCer 
●●) and complex GSLs (e.g., GM3 ●●◆) (F), which are then delivered to the plasma membrane via Golgi vesicular transport (G). At the plasma membrane 
level, SM can be converted into ceramide by sphingomyelinase (SMase), ceramide can then be transformed into sphingosine (Sph) by ceramidase (CDase), and 
sphingosine is converted into sphingosine 1-phosphate (S1P ■) by sphingosine kinases (SK1) (H). S1P is then transported across the membrane by specific 
transporters. Phosphorylation of sphingosine yielding to S1P because of the action of sphingosine kinase 2 (SK2) can occur at the mitochondria (I), nucleus (J), 
and ER (K). In the ER, S1P can be either irreversibly cleaved by S1P lyase or dephosphorylated back to sphingosine by a specific phosphatase (SPP1). Membrane 
sphingolipids are internalized via caveolae-dependent endocytosis and, in the lysosome, they are degraded by acidic forms of SMase and by different glycosidases 
(GCase) yielding ceramide that can be further hydrolyzed by the acid ceramidases (CDase) (L). The sphingosine formed in this reaction can escape the lysosome 
and can be metabolized to glycerophospholipids after phosphorylation by SK1 and cleavage by S1P lyase (SGPL) or it can be recycled for sphingolipid synthesis in 
the salvage pathway (M).
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On this basis, it is crucial to continue research to develop 
isoform-selective SK inhibitors (Table 1).
Literature has recently shown a cytotoxic effect of S1P 
(somewhat in contrast with the mainstream ceramide/S1P 
rheostat theory) in neurons (Hagen et al., 2011) and in beta-
cells of the pancreas (Hahn et al., 2017). In particular, it has been 
demonstrated that S1P induced i) apoptosis in hippocampal 
neurons (Moore et al., 1999) as well as ii) accumulation of 
S1P-induced apoptosis in neurons lacking S1P lyase (Hagen et al., 
2009). Moreover, Hagen et al. (2011) have shown that cerebellar 
neurons with abundant S1P lyase expression are the first to 
degenerate in S1P lyase-deficient mice. These findings give light 
to an important role of S1P lyase, which is ubiquitously expressed, 
in the regulation of physiological and pathophysiological aspects, 
as suggested also in the review by Choi and Saba (2019).
SPHINGOSINE 1-PHOSPHATE 
IN NEUROINFLAMMATION AND 
NEURODEGENERATION
Most acute or chronic neurodegenerative diseases are associated 
with changes in the total levels and/or in the composition of 
sphingolipids in different areas and cell populations in the nervous 
system. However, several questions remain without any answer on 
these sphingolipid alterations. Some sphingolipids are bioactive 
sphingolipids that are involved in the regulation of cell fate. 
Among them, S1P mediates crucial signaling pathways relevant 
to neurodegeneration (Hagen et al., 2011; Assi et al., 2013; Blaho 
and Hla, 2014; Proia and Hla, 2015; Pyne et al., 2018; Wang and 
Bieberich, 2018). In the brain, S1P regulates several fundamental 
processes, such as proliferation, survival, differentiation, and 
migration of all the different cell populations, including neurons, 
astrocytes, microglia, and oligodendrocytes, as well as infiltration 
of peripheral immune cells in the CNS during neuroinflammation 
FIGURE 3 | Extracellular and intracellular actions of S1P. Cells release S1P in the extracellular milieu through specific transporters [spinster homolog 2 (Spns2) or 
ABC transporters]. S1P in the extracellular milieu then binds to S1P receptors (S1P1–S1P5) located at the plasma membrane, thus inducing biological responses.
TABLE 1 | Research and clinical use of enzymes of S1P metabolism.
Inhibitor Target Indications for 
diseases
Reference
SKI-II SK1 and 
SK2
Cancers French et al., 2006; Santos 
and Lynch, 2015
SK1-I SK1 Cancers Paugh et al., 2008; 
Kapitonov et al., 2009
PF543 SK1 Sickle cell disease
Cancers
Zhang et al., 2014
ABC294640 SK2 Cancers
Lupus nephritis
Osteoarthritis
Diabetic retinopathy
Crohn’s disease
Rheumatoid arthritis
Ulcerative colitis
Santos and Lynch, 2015
Snider et al., 2013
Fitzpatrick et al., 2011b
Maines et al., 2006
Maines et al., 2010
Fitzpatrick et al., 2011a
Maines et al., 2008
K145 SK2 Cancers Liu et al., 2013b
LX-2931 S1P 
lyase
Cystic fibrosis Veltman et al., 2016
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(Kleger et al., 2007; Riccitelli et al., 2013; Smith et al., 2013; Marfia 
et al., 2014; Chiricozzi et al., 2018; Grassi et al., 2019). S1P can 
act both as an extracellular and as an intracellular mediator (Hait 
et al., 2009; Alvarez et al., 2010; Blaho and Hla, 2014; Proia and Hla, 
2015; Park et al., 2016). It regulates different signal transduction 
pathways in a cell type- and context-specific manner. When 
acting as an extracellular mediator, S1P effects are dependent on 
the type and expression levels of the different S1P receptor(s). 
Different S1P receptors are coupled to different G-proteins, thus 
regulating specific signaling pathways, including those mediated 
by MAPK, PI3K/Akt, and phospholipase C (Spiegel et al., 1998; 
Huang et al., 2011; Spiegel and Milstien, 2011; Kunkel et al., 2013; 
Blaho and Hla, 2014; Proia and Hla, 2015). On the other hand, 
different S1P intracellular targets have been recently discovered 
in several cell types, including neurons. It has been demonstrated 
in different cell types that S1P regulates the function of some 
proteins in different cellular compartments, such as the ER and 
nuclei; for example, HDACs, TRAF2, Hsp90, and HRP94 (Hait 
et al., 2009; Alvarez et al., 2010; Blaho and Hla, 2014; Proia and 
Hla, 2015; Park et al., 2016). In particular, three different nuclear 
transcription factors seem to be regulated by S1P-dependent 
pathways: 1) FOXO3a, which in PC12 cells is inhibited by the 
PI3K/Akt pathway (Safarian et al., 2015); 2) AP-1, regulated by 
the Jnk/p38/ERK pathway (Hsu et al., 2015; Jazvinscak Jembrek 
et al., 2015) and, in turn, controlling the mutual coregulation 
between sphingolipid-related genes (O’Neill et al., 2011; Huang 
et al., 2014; Wegner et al., 2014); 3) NF-κB, which is regulated 
via the tumor necrosis factor (TNF) receptor-associated factor 
TRAF2. In fact, TRAF2 can directly interact with SK1 and, on the 
other hand, it can be regulated by S1P as a receptor cofactor (Xia 
et al., 2002; Alvarez et al., 2010). In addition, histone deacetylases 
(HDAC1 and HDAC2), which can negatively regulate NF-κB 
via its deacetylation (Dai et al., 2005), are inhibited through S1P 
binding (Hait et al., 2009). The final effect of NF-κB influence on 
cell fate may vary, depending on the particular signaling context 
and by the underlying immune activation, among many other 
factors. Finally, S1P, by acting on its receptors and affecting the 
downstream PI3K/Akt, can inhibit GSK-3β (the crucial tau 
kinase) (Wang et al., 2015) and the proapoptotic protein Bad 
(Czubowicz et al., 2019).
It is now known that S1P has physiological functions in the 
CNS; several papers demonstrate that S1P plays an essential role 
in brain development (Mizugishi et al., 2005; Blaho and Hla, 
2014; Proia and Hla, 2015). Mizugishi et al. (2005) demonstrated 
that SK1 is highly expressed in mouse brain during normal 
development. Moreover, S1P depletion in SK1/SK2-double 
knockout mice (Mizugishi et al., 2005) caused severe defects in 
neural cell survival and in neurogenesis, leading to increased 
neural cell apoptosis and impaired neural tube closure, ultimately 
leading to an embryonic lethal phenotype. Remarkably, S1P1-null 
mice show a very similar neural phenotype, suggesting a pivotal 
role of S1P signaling in neurogenesis and brain development 
(Mizugishi et al., 2005; Blaho and Hla, 2014; Proia and Hla, 2015).
Abundant literature suggests important roles of S1P also for 
neuronal survival and for the maintenance of neuronal functions 
in adult brains. Different papers demonstrate that in hippocampal 
neurons, S1P is important for the stability of the presynaptic 
structure, for synaptic strength, and for the availability of 
synaptic vesicles (Brailoiu et al., 2002; Camoletto et al., 2009; 
Darios et al., 2009; Kanno et al., 2010; Riganti et al., 2016). On 
the other hand, under certain circumstances, S1P might become 
harmful. In fact, Mitroi et al. (2016) demonstrated that a certain 
S1P threshold concentration causes an increase in basal calcium 
in neurons that impairs presynaptic architecture most probably 
via a UPS-mediated mechanism.
Moruno Manchon et al. (2015, 2016) demonstrated that S1P 
promotes prosurvival neuronal autophagy; in particular, they 
have shown that SK1 enhances autophagic activity, whereas 
SGPL1 reduces this activity. Autophagy plays a crucial role 
for neuron survival; in fact, this process allows neurons to get 
rid of damaged and aggregated proteins and organelles during 
different conditions, such as aging and diseases, in particular, to 
counteract cell death induced by ceramide or other pathogens 
(Moruno Manchon et al., 2015; Moruno Manchon et al., 2016; 
Moruno-Manchon et al., 2018).
However, the role of S1P metabolism in brain autophagy is very 
complex. In fact, in contrast to these results, Mitroi et al. (2017) 
demonstrated that the deficiency of SGPL exerted a block on the 
autophagic flux. The authors demonstrated that depletion of SGPL, 
increasing S1P levels while decreasing ethanolamine phosphate 
and consequently phosphatidylethanolamine, blocks autophagy at 
the initial stages (Mitroi et al., 2017). These findings suggest that 
in neurons, the increase of S1P and the simultaneous decrease of 
phosphatidylethanolamine caused by the modulation of SGLP both 
affect autophagy even if in an antagonistic way (Mitroi et al., 2017).
Altogether, the role of S1P as a bioactive lipid in the nervous 
system appears to be dual (Van Echten-Deckert and Alam, 2018). 
On one hand, as described above, it is essential for proper brain 
development; on the other hand, its detrimental effects and 
cytotoxic effects on some particular neuronal populations have 
been documented (Van Echten-Deckert et al., 2014).
The regulation of S1P concentration in the different cerebral 
areas suggests a specific function of S1P in different brain regions.
Recently, thanks to the approval by the Food and Drug 
Administration (FDA) of the sphingosine analog and S1P1 
functional antagonist fingolimod {FTY720, Gilenya, 2-amino-
2[2-(4-octylphenyl)ethyl]-1,3-propanediol}, the functions of S1P 
in neuroinflammation processes regarding neurodegeneration 
attracted the attention of the scientific community. Microglia 
activation is emerging as one of the crucial factors contributing 
to the onset of neuroinflammation associated with different 
neurodegenerative diseases.
Nayak et al. (2010) demonstrated that in activated microglia, 
SK1 expression is upregulated. In turn, SK1 affects the 
production of proinflammatory cytokines and nitric oxide in 
lipopolysaccharide (LPS)-treated microglia (Nayak et al., 2010). 
In other cell types, treatment with LPS was able to activate the 
SK1/S1P signaling pathway by inducing the translocation of 
SK1 to the plasma membrane, leading to increased production 
of S1P (Hammad et al., 2008; Fernandez-Pisonero et al., 2012). 
The administration of exogenous S1P to activated microglia 
increased the inflammatory response, inducing the production 
of proinflammatory cytokines and neurotoxins (Assi et al., 2013; 
Lv et al., 2016). Altogether, data in the literature suggest that the 
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S1P/SK1 pathway, acting as an autocrine or paracrine factor, is 
involved in the inflammatory response of activated microglia, 
regulating the release of proinflammatory factors by microglia.
On the other hand, it has been shown that under proinflammatory 
conditions, SK1 and S1P3 in astrocytes are functionally upregulated 
(Fischer et al., 2011). Moreover, treatment of astrocytes with IL-1 
induces the expression of SK1 and, in turn, exposure to exogenous 
S1P induces astrogliosis (Sorensen et al., 2003; Paugh et al., 2009). 
In a mouse model of multiple sclerosis (MS), it has been shown that 
particular clusters of astrocytes are activated, and astrocyte activation 
progressively expand along white matter tracts. Moreover, the loss of 
astrocytic S1P1 limited the extent of astrocyte activation (Choi et al., 
2011; Dusaban et al., 2017). The role of S1P1 in astrocytes seems to 
be essential not only for astrocyte’s own functions but also for the 
interplay between astrocytes and other cell types. Indeed, modulation 
of S1P1 by fingolimod in astrocytes effectively suppressed different 
neurodegeneration-inducing pathways mediated by astrocytes, 
but also by microglia, and by CNS-infiltrating activated leukocytes 
(Karunakaran and Van Echten-Deckert, 2017; Rothhammer et al., 
2017; Wang and Bieberich, 2018).
Considering the role of S1P in the development and physiological 
homeostasis of the nervous system and its emerging importance in 
neuroinflammation, it is not surprising that dysregulation of S1P 
metabolism and S1P-mediated signaling is emerging as a common 
trait and an important causative factor in various neurodegenerative 
diseases, including MS, AD, PD, and Huntington disease (HD). 
The knowledge about the role of S1P in these affections is briefly 
outlined in the following sections of this review.
SPHINGOSINE 1-PHOSPHATE AND 
MULTIPLE SCLEROSIS
MS is a chronic inflammatory disease of the CNS, in which the 
inflammatory process is associated with a destruction of myelin, 
leading to the appearance of large focal lesions of demyelination. 
Axonal damage and loss as consequences of the inflammatory 
demyelination also occur, even if at variable extents. Active 
remyelination processes can at least in part repair myelin lesions, 
whereas axonal loss is permanent and irreversible.
MS is primarily considered an autoimmune neurodegenerative 
disease, that is, a disease caused by an adaptive immune 
response to self-antigens. In MS, activated myelin-reactive T 
cells [in particular, T helper 1 cells (Th1)] are recruited from the 
periphery to the CNS, leading to the activation of microglia and 
to the recruitment of circulating macrophages. Consistently with 
this, fingolimod has proven to be an effective disease-modifying 
drug for the treatment of relapsing–remitting MS (RR-MS).
Fingolimod, a structural analog of sphingosine, is converted 
in vivo to fingolimod-P, a structural analog of S1P, which acts as 
a nonselective agonist for S1P1, S1P3, S1P4, and S1P5 receptors 
(lacking activity on S1P2). It acts as a functional antagonist of 
S1P receptors, causing the irreversible internalization and 
degradation of bound S1P receptors (thus preventing their 
recycling back to the cell surface) (Figure 4).
Fingolimod is effective on MS by preventing the recruitment of 
T cells, expressing S1P1 and S1P3 receptors, with their consequent 
redistribution to secondary lymphoid organs, and preventing 
FIGURE 4 | Comparative signaling pathways of S1P and FTY720-P. Both S1P (left panel) and FTY720-P (right panel) stimulate the internalization of S1P receptor. 
The receptor that binds S1P is recycled back to the cell surface, whereas FTY720-P causes irreversible internalization and degradation of bound S1P receptor.
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invasion of auto-aggressive T cells to the CNS. However, the 
heterogeneity of human MS and the comparison between the 
human disease and the different animal models suggest that 
additional factors other than Th1-mediated autoimmunity 
are relevant to lead from primary demyelination to a chronic 
inflammatory lesion. It is worth to note that primates, differently 
from mice, do not develop demyelination because of pure T cell-
mediated inflammation. In fact, fingolimod effectively decreased 
astrocyte and microglia activation in a non-T cell animal model 
of demyelination, the cuprizone mouse model (Kim et al., 2011).
A significant contribution to the progression of the disease 
is likely given by circulating demyelinating antibodies against 
myelin surface components, most notably the anti-myelin 
oligodendrocyte glycoprotein antibodies, occurring in a 
significant proportion of MS patients (Linington et al., 1988; 
Ramanathan et al., 2016; Spadaro et al., 2018). In addition, cell 
populations resident in the lesion niche, most notably astrocytes 
and microglia, might critically affect both oligodendrocyte injury 
and axonal degeneration (Mayo et al., 2012). Indeed, changes in 
the expression of 13 different growth factors, known to regulate 
the development and maintenance of oligodendrocytes, were 
highlighted during demyelination and remyelination in the 
murine cuprizone model of toxic demyelination (Gudi et al., 
2011). In particular, in lesion areas, IGF-1 and CNTF were 
elevated in astrocytes, whereas GDNF, IGF-1, and FGF were 
detected at high levels in microglia.
In MS, oligodendrocyte loss and myelin damage can be 
observed in early lesions, even in the absence of infiltrates 
of immune cells from the periphery. On the other hand, early 
activation and proliferation of microglia and astrocytes are 
consistently present in MS lesions. Several pieces of evidence 
suggest that S1P signaling in these cell populations might be 
relevant to the progression of the disease, opening up new 
perspectives for drugs acting on the S1P axis in the therapy of 
MS (reviewed in Groves et al., 2013; Farez and Correale, 2016).
Altered sphingolipid metabolism and altered sphingolipid-
dependent signaling in reactive astrocytes might contribute to 
oligodendrocyte damage in MS (Kim et al., 2012). Ceramide 
accumulated in reactive astrocytes in active lesions of MS and 
in a non-T cell animal model of demyelination (the cuprizone 
mouse model). Ceramide accumulation was consequent to the 
upregulation of serine palmitoyltransferase in reactive astrocytes. 
In culture, ceramide acted synergistically with TNF, inducing 
apoptosis of oligodendrocytes (an astrocyte-dependent event). 
Concomitantly, sphingosine was accumulated whereas S1P levels 
were decreased. These alterations in sphingolipid metabolism 
were restored upon active remyelination.
It has been shown that sphingosine kinase 1 and S1P3 are 
upregulated in reactive astrocytes present at the lesion site 
or in cultured rat astrocytes treated with LPS. S1P induced 
secretion of CXCL1 in astrocytes, and secretion was increased in 
astrocytes pretreated with LPS. Thus, ceramide/S1P pathway in 
astrocytes is relevant for astrocyte activation, and in MS, it could 
be detrimental, enhancing astrogliosis, or beneficial, through 
increased remyelination sustained by CXCL1 (Fischer et al., 2011).
As mentioned above, the main therapeutic effect of fingolimod 
in MS seems to be related to its ability to prevent migration of 
auto-aggressive lymphocytes to the CNS. However, because S1P 
receptors are widely expressed in the CNS, fingolimod easily 
crosses the blood–brain barrier (BBB) and the effect on MS is 
at least in part independent of the effect on the migration of 
immune cells from the periphery (Meno-Tetang et al., 2006; 
Foster et al., 2007; Chun and Hartung, 2010).
In fact, emerging evidence indicates that the efficacy of 
fingolimod in MS is at least in part caused by its direct effects 
on the CNS. S1P signaling effects relevant for MS likely involve 
different neural cell types (astrocytes, oligodendrocytes, neurons, 
microglia, and dendritic cells); however, very strong evidence 
indicates a primary role of astrocytes in the direct effects of 
fingolimod on the CNS. Astrocytes express S1P receptors, 
mainly S1P1 and S1P3. S1P1 and S1P3 are upregulated in reactive 
astrocytes present in demyelinating and chronic MS lesions. S1P 
modifies astrocyte morphology and increases the expression of 
GFAP, marker of astrogliosis. Fingolimod stimulates migration 
of cultured astrocytes, whereas it acts in vivo as a functional 
antagonist of astrocyte S1P1.
In experimental autoimmune encephalomyelitis (EAE), 
an experimental paradigm of Th1-mediated demyelinating 
disease, fingolimod is highly effective; however, its effects are 
abolished in animals selectively lacking the expression of S1P1 
in astrocytes (even if the receptor expression and function in 
immune cells are preserved) (Choi et al., 2011). As an endpoint, 
fingolimod appears to be able to promote remyelination by 
acting on oligodendrocytes, microglia, or astrocytes. In addition, 
fingolimod was effective in increasing remyelination in a rat CNS 
reaggregate spheroid cell culture model (a CNS environment 
devoid of immune system effects) upon lysoPC-induced transient 
demyelination. Increased remyelination was associated with 
partial inhibition of microglia activation (Jackson et al., 2011). In 
summary, downmodulation of S1P1 receptors in astrocytes upon 
fingolimod treatment causes reduced astrocyte activation and 
improves the communication of astrocytes with other CNS cells, 
resulting in reduced demyelination or improved remyelination.
S1P signaling as a pharmacological target in MS is relevant 
not only in astrocytes but also in microglia. As mentioned above, 
microglia can contribute to the release of factors positively 
affecting remyelination. On the other hand, fingolimod in 
cultured microglia was able to suppress via binding of S1P1 
the production of relevant proinflammatory cytokines, such as 
TNFα, IL-1β, and IL-6 (Choi et al., 2011).
A further layer of complexity in the possibility to affect the 
S1P/S1P receptor axis in MS is revealed by studies suggesting 
that fingolimod might be effective in modifying some disease 
parameters by acting as an agonist, rather than a functional 
antagonist, of given S1P receptors. In addition to motor 
deficits, over 50% of MS patients suffer from neuropathic pain, 
a debilitating symptom that dramatically affects the patients’ 
quality of life. In EAE mice, painlike behavior appears early on 
and well before the motor symptoms develop. In this model, 
fingolimod was able to reduce hyperalgesia by acting as an 
S1P1 agonist at the central level, inhibiting spinal nociceptive 
processing (Doolen et al., 2018). This would suggest that novel 
site- or receptor-specific drugs could be effective in ameliorating 
the central neuropathic pain.
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Finally, despite the prevailing view of T cell-mediated 
inflammation as the main culprit in the pathogenesis of MS 
lesions, some data suggest that the inflammatory response and 
more in general the contribution of the immune system might 
have a protective role or a role in the repair of myelin lesions. 
For example, it has been shown that inflammatory cells within 
MS lesions might release neurotrophic factors (Kerschensteiner 
et al., 1999) or factors able to stimulate the physiological, per se 
insufficient, mechanism or remyelination (Diemel et al., 1998). 
On the other hand, some naturally occurring autoantibodies, 
a subset of monoclonal antibodies that is a part of the normal 
immunoglobulin repertoire, were able to stimulate remyelination 
in CNS demyelinating diseases (Rodriguez et al., 2009). rHIgM22, 
the recombinant form of a naturally occurring antibody isolated 
from a patient with Waldenström macroglobulinemia, was 
able to bind selectively to myelin in vitro and to the surface of 
cultured oligodendrocytes. It was shown to enter the CNS and 
to accumulate at the lesion sites in MS (Pirko et al., 2004) and 
to promote remyelination in Theiler’s murine encephalomyelitis 
virus (Warrington et al., 2000)-, lysolecithin (Bieber et al., 2002)-, 
and cuprizone-induced (Mullin et al., 2017) demyelination 
models of MS. A 16-site Phase 1 clinical trial in MS patients 
completed in 2015 (NCT0183867) showed no dose-limiting 
toxicities, no serious treatment-emergent adverse events, and 
the presence of the antibody in the CFS in all patients (Eisen 
et al., 2017). Although some studies suggest that the rHIgM22 
remyelination-promoting effect is exerted directly on myelin-
producing cells (Watzlawik et al., 2010; Watzlawik et al., 
2013), others suggest that it acts on other cell types present in 
the lesion niche, including astrocytes (Paz Soldan et al., 2003) 
and microglia (Zorina et al., 2018). We recently showed that 
rHIgM22 stimulated the proliferation of astrocytes in mixed 
glial cells because of the increased production and release of S1P, 
suggesting that S1P signaling might be significant in the interplay 
of different cell types involved in the complex series of events 
eventually leading to myelin repair (Grassi et al., 2019).
SPHINGOSINE 1-PHOSPHATE AND 
ALZHEIMER’S DISEASE
AD is hallmarked by the accumulation of intraneuronal 
aggregates of hyperphosphorylated tau protein and deposition 
of extracellular oligomer amyloid beta peptide (predominantly 
Aβ42 and Aβ40). Evidence strongly suggests a critical role 
of Aβ, which derives from the proteolytic processing of the 
amyloid precursor protein (APP), in the initiation of AD 
(Kozlov et al., 2017).
The possible role of S1P in AD is currently quite controversial. 
There is evidence suggesting a direct role of S1P in the initiation 
and progression of AD. S1P was found to directly interact and 
stimulate the proteolytic activity of the β-secretase BACE1, 
the rate-limiting enzyme for Aβ production. Moreover, 
overexpression of SGPL1 and inhibition or knockdown of SKs 
reduced BACE1 activity, in vitro and in vivo, with consequent 
decreased Aβ secretion, suggesting a correlation between levels 
of S1P and those of Aβ (Hagen et al., 2011; Takasugi et al., 2011). 
A study of SGPL1-deficient mice also revealed that S1P elevated 
levels to exert a neurotoxic effect mediated by a calcium/calpain/
CDK5 mechanism (Hagen et al., 2011). Moreover, SGPL1 
deficiency was also associated with hyperphosphorylation of 
tau, accumulation of APP, and impaired lysosomal activity 
(Hagen et al., 2011; Karaca et al., 2014). AD brains also showed 
an increased SK2 activity (Takasugi et al., 2011), and ERK 
and Fyn kinase, both known modulators of this enzyme, have 
been implicated in Aβ-mediated neurotoxicity (Olivera et al., 
2006; Hait et al., 2007; Crews and Masliah, 2010), which could 
suggest that SK2 upregulation might be mediated by aberrant 
phosphorylation by Fyn and/or ERK. On the other hand, 
consistently with the prosurvival and antiapoptotic effects of 
S1P, the S1P/sphingosine ratio is decreased in postmortem AD 
brains and hippocampus, and the decrease is associated with 
the reduction of SK1 activity. Increased levels of SGPL1 and 
S1P phosphatase have also been reported in these brains (Katsel 
et al., 2007; He et al., 2010; Ceccom et al., 2014; Couttas et al., 
2014), indicating a protective role of S1P in AD. SKs have also 
been shown to exert a protective influence in Aβ toxicity. Their 
overexpression reduced the toxic effects of Aβ (Gomez-Brouchet 
et al., 2007) whereas SK1 silencing in APP/PS1 mice led to an 
increased secretion of Aβ and, consequently, an increased 
Aβ-induced cell death (Zhang et al., 2013). Suppression of SK1 
by miRNA 125b, which is abundant in AD, correlated with an 
increased Aβ production in vitro (Jin et al., 2018).
The exact mechanism through which S1P could exert its 
protective role is still unclear; however, a few studies (Gomez-
Munoz et al., 2003; Malaplate-Armand et al., 2006; He et al., 
2010) suggest that S1P might act by inhibiting the activation 
of acid sphingomyelinase, whose activity has been found to be 
increased in AD brains (Gomez-Munoz et al., 2003).
SK2 also has a controversial role in AD. Some authors, as 
previously mentioned, showed an increase in SK2 activity in the 
frontal cortex of AD brains (Takasugi et al., 2011), whereas others 
reported a decreased activity in temporal cortex and hippocampus 
(Couttas et al., 2014). These results, however, may simply reflect 
the complexity of SK regulation and function, and subcellular 
localization may play a role in SK2 expression in AD. Interestingly 
it has been observed that in AD brains, the equilibrium between 
the nuclear and the cytoplasmic SK2 was altered. It has been 
reported that SK2 in these brains preferentially localized in the 
nucleus, whereas the cytoplasmic expression of the enzyme 
inversely correlated to Aβ deposits (Dominguez et al., 2018).
Fingolimod, the immunomodulatory analogue of S1P, has 
been tested in AD models. Fingolimod was able to reduce the 
S1P Aβ-induced neuronal damage in rat hippocampus and 
improve the consequent cognitive impairment (Asle-Rousta 
et al., 2013a, Asle-Rousta et al., 2013b). In a mouse model of 
AD, treatment with fingolimod lad to a reduction of soluble 
and insoluble Aβ and to decreased Aβ plaque density (Aytan 
et  al., 2016). Furthermore, both fingolimod and KRP203, 
another S1P analogue, decrease Aβ generation in neuronal cells 
(Takasugi et al., 2013). The effect of fingolimod was also tested 
in transgenic mice overexpressing APP and presenilin 1 (APP/
PS1 mice). In this model, Aβ accumulation and loss of neuronal 
function are coupled with augmented BBB permeability 
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and with the activation of astrocytes and microglia (Kelly 
et al., 2013; Mcmanus et al., 2014; Minogue et al., 2014). A 
reduction in both accumulation of Aβ and astroglial activation 
was observed after treatment with fingolimod. Moreover, the 
treatment also increased the phagocytic activity of astrocytes, 
suggesting that the decrease in Aβ accumulation in the treated 
mice could be a consequence of this enhanced phagocytic 
function (Mcmanus et al., 2017).
Fingolimod’s exact mechanism in AD however remains to 
be elucidated; however, the protective effect of fingolimod in 
neurons was associated with an altered expression of MAPKs and 
some inflammatory markers (Hemmati et al., 2013).
SPHINGOSINE 1-PHOSPHATE AND 
PARKINSON’S DISEASE
PD is one of the most common neurodegenerative disorders, 
second only to AD, and is clinically defined by the degeneration 
or death of dopaminergic neurons in the substantia nigra 
accompanied by the formation of aggregates of alpha-synuclein 
and ubiquitin, called Lewy bodies (Beitz, 2014).
In neuronal cells (SH-SY5Y) treated with 1-methyl-4-
phenylpyridinium (MPP+), an active metabolite of MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), there is a 
reduction in SK1 gene expression and protein levels, with a 
concomitant increase of SGPL1 that leads to enhanced reactive 
oxygen species (ROS) generation (Pyszko and Strosznajder, 2014a; 
Pyszko and Strosznajder, 2014b). Moreover, pharmacological 
inhibition of SK1 was shown to suppress prosurvival PI3K/Akt 
phosphorylation, activation and upregulation of proapoptotic 
proteins, cytochrome c release from mitochondria, and caspase-
dependent apoptosis in these cells (Pyszko and Strosznajder, 
2014a; Pyszko and Strosznajder, 2014b). In the same experimental 
model, inhibition of SK1 and SK2 also led to an increased 
secretion of alpha-synuclein, a protein able to negatively regulate 
S1P1 signalling (Pyszko and Strosznajder, 2014a; Pyszko and 
Strosznajder, 2014b; Badawy et al., 2018). Interestingly, treatment 
with pramipexole, a D2/D3 receptor agonist commonly used in 
PD therapy, partially reversed SK1 inhibition in the MPP+ model 
(Motyl et al., 2018).
In MPP+-treated neuronal cells, S1P administration showed 
neuroprotective effects. The treatment with exogenous S1P in fact 
significantly increased cell viability mainly through activation 
of S1P1 receptor-mediated signalling, reduced the mRNA level 
of proapoptotic proteins such as Bax and Hrk, and decreased 
cytochrome c levels in a mitochondrial fraction, leading to 
caspase-dependent poly(ADP-ribose) polymerase-1 proteolysis 
(Pyszko and Strosznajder, 2014a; Pyszko and Strosznajder, 
2014b). Interestingly, S1P1 was recently proposed as a candidate 
gene for a newly identified PD susceptibility locus (Hill-Burns 
et al., 2014), supporting the potential role for S1P1 signalling 
in regulating midbrain dopaminergic neuron survival and/or 
function. Phospholipid phosphatase 3, an integral membrane 
glycoprotein involved in the modulation of S1P metabolism 
and signalling in the brain (Lopez-Juarez et al., 2011), has also 
been implicated in PD, and its inactivation in CNS progenitor 
cells caused a severe downregulation of S1P1 in the adult ventral 
midbrain and in the cerebellum (Lopez-Juarez et al., 2011; 
Gomez-Lopez et al., 2016).
A marked decrease of SK2 levels has been reported 
in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treated C57BL/6 mice, a PD mouse 
model (Sivasubramanian et al., 2015). Moreover, SK2 inhibition 
in MN6D dopaminergic neurons decreased the expression of 
genes for the regulation of mitochondrial function and led to 
marked ATP depletion and reduction of superoxide dismutase 
2 levels. An increase in the ROS levels was also observed 
(Sivasubramanian et al., 2015).
Administration of fingolimod protected against 
neurodegeneration and behavioral effects in mouse PD models 
induced by MPTP, 6-hydroxydopamine, or rotenone through 
S1P1 signalling and probably Akt (Ren et al., 2017; Zhao et al., 
2017; Motyl et al., 2018); however, the S1P analogue was not 
effective in a PD model induced by subacute administration of 
MPTP (Komnig et al., 2018). Cellular studies applying newly 
modified versions of fingolimod referred to as C2 moiety 
(FTY720 C2 or FTY720-Mitoxy) have shown that these 
compounds increase BDNF levels, activate protein phosphatase 
2A, whose activity is impaired in PD, and protect MN9D cells 
against TNFα-induced cell death (Vargas-Medrano et al., 2014). 
Long-term oral administration of fingolimod reduced alpha-
synuclein aggregation and increased BDNF levels in transgenic 
mice overexpressing mutant human alpha-synuclein (Vidal-
Martinez et al., 2016). There are also several reports indicating 
a fingolimod neuroprotective effect in PD models induced by 
toxins. For example, in C57BL/6 mice subjected to acute MPTP 
intoxication, there was a reduced expression and activity of SK1. 
This study also showed that fingolimod exerts neuroprotective 
effects comparable to pramipexole, a dopamine D2/D3 receptor 
agonist (Motyl et al., 2018).
SPHINGOSINE 1-PHOSPHATE AND 
HUNTINGTON’S DISEASE
HD is an inherited neurodegenerative brain disease characterized 
by the progressive degeneration of the striatum and cortex, with 
consequent motor, cognitive, and behavioral symptoms. It is 
caused by a dominant mutation, which leads to the expansion of a 
CAG trinucleotide repeat in the gene encoding for the huntingtin 
protein. The consequence of the mutation is the expression of 
a protein with a polyglutamine stretch in the N-terminal region 
much longer than in the wild type (Jimenez-Sanchez et al., 2017). 
The exact biological function of huntingtin is poorly understood, 
but it is highly expressed in brain where it seems to be relevant 
for neuronal development and metabolism.
Recent studies indicate that the expression of S1P-
metabolizing enzymes is altered in several HD models, including 
animal models, human brain tissues, and cultured cells (Di Pardo 
et al., 2017; Pirhaji et al., 2017). Upregulation of SGPL1 and 
reduced expression of SK1 are detectable in human postmortem 
brains and in striatal tissues of two of the most commonly used 
HD animal models (R6/2 and YAC128 mice), even at an early 
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stage of the disease (Di Pardo et al., 2017; Pirhaji et al., 2017). 
Moreover, evidence indicates that miRNA 125b expression, 
which is downregulated in R6/2 mice, negatively regulates gene 
expression of SGPL1 (Ghose et al., 2011; Yang et al., 2016). 
Furthermore, it has been demonstrated that cytoplasmic SK1 is 
involved in the regulation of huntingtin degradation (Moruno 
Manchon et al., 2015). R6/2 mice also exhibit increased SK2 and 
reduced S1P levels (Di Pardo et al., 2017; Pirhaji et al., 2017). This 
reduction of S1P levels could be a potential therapeutic target. 
In fact, fingolimod was able to improve neuronal activity and 
motor function, reduce brain atrophy, and increase R6/2 animal 
survival (Di Pardo et al., 2014). Moreover, both fingolimod and 
the pharmacological activator K6PC-6 significantly reduced 
apoptosis in an HD cellular model and increased the activation 
of Akt and Erk signalling pathways (Di Pardo et al., 2017), whose 
regulation is known to be defective in HD (Bowles and Jones, 
2014). In R6/2 mice, fingolimod also enhanced phosphorylation 
of huntingtin at the serine-13/16 residues. This might contribute 
to the protective effect of fingolimod because this posttranslational 
modification was associated with reduced toxicity of mutated 
huntingtin (Atwal et al., 2011; Di Pardo et al., 2014). Moreover, 
reduced synthesis of GM1 gangliosides was found in HD patients 
and animal models. Lower GM1 levels were associated with 
higher sensitivity to neuronal death, and artificial reduction of 
GM1 synthesis increases the apoptotic rate in normal striatal 
neurons. It has been shown that GM1 administration to HD mice 
was able to improve motor symptoms (Di Pardo et al., 2012). 
Remarkably, the molecular mechanism of this effect seems to be 
mediated by the GM1-induced phosphorylation of huntingtin. 
On the other hand, fingolimod was able to restore normal levels 
of GM1 in HD mice (Maglione et al., 2010; Di Pardo et al., 2014). 
This is an intriguing finding, suggesting that fingolimod’s effects 
on sphingolipid metabolism might be much more complex than 
argued on the basis of its efficacy as a functional antagonist of 
S1P receptors.
Fingolimod also improved synaptic plasticity and memory 
in the R6/1 mouse model of HD by regulating BDNF signalling 
and astroglial reactivity. Fingolimod administration prevented 
overactivation of NF-κB signalling in R6/1 hippocampus, leading 
to a decrease in TNFα and induced nitric oxide synthase (iNOS) 
levels. This reduction correlates with the normalization of 
p75NTR expression in the hippocampus, consequently preventing 
p75NTR/TrkB imbalance, a critical mechanism for memory and 
synaptic function in HD (Brito et al., 2014; Miguez et al., 2015). 
Moreover, fingolimod increased cAMP levels and promoted 
phosphorylation of CREB and RhoA in the hippocampus of 
R6/1 mice, supporting its role in the enhancement of synaptic 
plasticity (Miguez et al., 2015). Interestingly, these results 
also provide a possible explanation for fingolimod-induced 
cognitive benefits in AD because both TNFα and p75NTR are 
overexpressed in AD patients, and p75NTR downregulation 
is able to prevent cognitive and neurite dysfunction in an AD 
mouse model (Hu et al., 2002; Alvarez et al., 2007; Asle-Rousta 
et al., 2013a; Knowles et al., 2013; Fukumoto et al., 2014).
Modulation of SK2 and SGPL1 may also exert protective effects 
in HD. Administration of two SK2 selective inhibitors (K145 
and EMD56773) markedly reduced apoptosis (Di Pardo et al., 
2017). On the other hand, inhibition of SGPL1 (using 2-acetyl-5-
tetrahydroxybutyl imidazole or 4-deoxypryridoxine) also reduced 
cell death. This effect was associated with the inhibition of HDAC 
activity, which in turn resulted in increased levels of histone H3 
acetylation. Because histone H3 deacetylation was previously 
reported to be reduced in several HD models, this could explain 
the protective effect of SGPL1 inhibition in this disease (Buckley 
et al., 2010; Di Pardo et al., 2017; Pirhaji et al., 2017).
SK2 has also been implicated in HDAC regulation. In 
fact, it has been reported that increasing levels of S1P in the 
nucleus by overexpressing SK2 lead to histone deacetylases 1 
and 2 inhibition. S1P directly binds to these deacetylases while 
SK2 forms a complex with them, which inhibits their activity 
(Hait et al., 2009; Hait et al., 2014). Whereas SK2 might exert 
a neuroprotective role through HDAC inhibition, it has been 
observed that its overexpression is neurotoxic for cultured 
striatal and cortical neurons in a dose-dependent manner. In 
these neuronal models and in the BACHD mouse model of HD, 
SK2 is hyperphosphorylated and promotes the formation of 
double-strand breaks. Interestingly, a small molecule inhibitor 
of SK2, ABC294640, was able to mitigate DNA damage and 
neurotoxicity and protect against degeneration on two mouse 
models of HD (Moruno-Manchon et al., 2017).
Stimulation of S1P5 in the R6/2 models using the selective 
agonist A-971432 was also considered as a potential therapeutic 
approach for HD. Chronic administration of the agonist slowed 
down the progression of the disease and prolonged the life span 
of R6/2 mice. These effects were associated to the activation of the 
prosurvival pathways (AKT, BDNF, ERK) and with a reduction 
of mutant huntingtin aggregation. Moreover, A-971432 also 
protected BBB homeostasis in these mice, and when administered 
early in the disease, it completely protected them from the classic 
progressive motor deficit and preserved BBB integrity (Di Pardo 
et al., 2018).
S1P5 is known to be involved in the regulation of BBB tight 
junctions, and the effect of its agonist A-971432 was associated 
with an increased expression of the tight junction proteins 
occludin and claudin-5 (Feldman et al., 2005; Piontek et al., 2008; 
Van Doorn et al., 2012).
FINGOLIMOD AND BEYOND
The immunomodulatory drug fingolimod (FTY720) is the first 
drug approved for oral treatment of relapsing-remitting MS 
(RR-MS) (Kappos et al., 2006; Brinkmann et al., 2010) because 
of its impressive efficacy and good tolerability. Fingolimod is 
phosphorylated to form fingolimod-P, very similar to S1P.
Pharmacologically, fingolimod acts as a nonselective 
agonist of S1P receptors, with the exception of S1P2, and as a 
selective functional antagonist of the S1P1 subtype, the main 
S1P receptor expressed in different tissues, including brain and 
immune system cells (Blaho and Hla, 2014), inducing receptor 
downregulation (Pyne et al., 2016). Fingolimod-P initially binds 
to and activates S1P1. After being engaged by fingolimod-P, 
S1P1 is subsequently internalized and degraded (Huwiler and 
Zangemeister-Wittke, 2018).
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Although effective in ameliorating the symptoms and delaying 
the worsening in RR-MS, fingolimod has very limited effect on 
the progressive forms of MS (Farez and Correale, 2016). For this 
reason, various selective S1P receptor modulators are currently 
under investigation in preclinical studies and in some cases in 
clinical trials to test their clinical use in primary or secondary 
progressive MS (Mao-Draayer et al., 2017).
Seeking for valuable alternatives to fingolimod, new-generation 
S1P receptor modulators have been developed, characterized by a 
higher selectivity and improved pharmacokinetic performance 
and tolerability (Pyne et al., 2016). A number of S1P receptor 
drugs in clinical trials of MS are reported in Table 2 (Pyne et al., 
2016; O’sullivan and Dev, 2017). Fingolimod is used in MS; 
however, ongoing preclinical studies suggest the use of fingolimod 
for different brain diseases, including AD, HD, and PD. In Table 3, 
fingolimod current clinical trials related to other brain diseases 
other than MS are summarized (O’sullivan and Dev, 2017).
The role played by S1P in the development of neurodegenerative 
diseases like MS makes S1P receptors the most interesting 
pharmacological targets.
As mentioned above, the first molecule used as therapeutic agent 
for MS is fingolimod, which acts as an S1P1,3,4,5 modulator (Huwiler 
and Zangemeister-Wittke, 2018). Fingolimod, which in 2010 has 
been approved by the FDA for the treatment of RR-MS, is a prodrug 
whose chemical structure is very similar to that of sphingosine. Its 
phosphorylation turns it into (S)-FTY720-monophosphate, an 
S1P analog (Sushil and Batra, 2012). This phosphate-derivative 
undergoes the action of the same phosphatases (SPP1 and SPP2) 
that dephosphorylate S1P. To overcome this problem and in the 
wake of fingolimod’s success, structure-activity relationship (SAR) 
studies performed on FTY720-phosphate have been used to design 
several fingolimod-phosphate derivatives and nonhydrolyzable 
phosphonate (reviewed in Marciniak et al., 2018, and Stepanovska 
and Huwiler, 2019).
The key features of the agonists obtained after these modifications 
can be summarized as follows: polar head, aromatic region, and 
lipophilic tail (Liu et al., 2019). Indeed, not only molecules strictly 
similar to S1P are able to interact with S1P receptors.
Introduction of a carboxylic acid head group that does not 
require activation for bioavailability led to the development of 
a compound designated as BAF312, commercially known as 
siponimod (Figure 5), which entered phase III clinical studies 
on secondary progressive MS (SPMS) patients. This molecule 
displays potent agonism on S1P1 and S1P5 while completely 
sparing S1P3, and the highest selectivity toward S1P1 and S1P5 
is caused by the increased rigidity in the lipophilic alkyl chain of 
fingolimod (Pan et al., 2013).
Another S1PR modulator and MS drug candidate is ONO-
4641, commercially named ceralifimod (Figure 5). This molecule 
has a chemical structure similar to that of siponimod and also acts 
specifically on S1P1 and S1P5. A phase II clinical trial was concluded 
in 2012; however, at the moment, it is not clear what future 
developments the molecule will have (Subei and Cohen, 2015).
About the series of oxadiazole-based S1P agonists with high 
selectivity for S1P1 and S1P5 receptor, the derivative disubstituted 
on terminal benzene ring and with a terminal hydroxyl group 
RPC1063, named ozanimod (Figure 5) (Scott et al., 2016), has 
entered phase III clinical trials. Ozanimod, one of the most 
promising molecules for MS, has minor adverse effects and 
shows superior receptor specificity if compared to fingolimod, 
siponimod, and ponesimod (Westad et al., 2017).
Ponesimod (ACT-128800) (Figure 5) is another class of 
S1P1 receptor agonists based on the 2-imino-thiazolidin-
4-one scaffold, with a diol substituent that does not require 
phosphorylation for the acidity. This compound has been selected 
for clinical development (Bolli et al., 2010), and its selectivity for 
S1P1 is approximately 650-fold higher compared with the natural 
ligand S1P (D’ambrosio et al., 2016).
Several other molecules have been developed and entered in 
phase I clinical trials, but other studies are needed to design more 
potent and selective immunomodulatory drugs without causing 
major adverse effects.
CONCLUSIONS
Deregulation of sphingolipid metabolism is a common feature 
of a number of brain diseases, even in the absence of specific 
known defects of sphingolipid metabolic enzymes and/or 
sphingolipid intracellular traffic (Piccinini et al., 2010). Thus, 
researchers in this field have frequently explored the concept 
of targeting sphingolipid metabolism to address brain diseases. 
However, the translation of basic research to therapeutic 
opportunities in the case of complex glycosphingolipids has been 
so far unsuccessful. The only notable exception is represented 
by the potential use of a glucosylceramide synthase inhibitor, 
GZ667161, for the treatment of PD patients associated with 
mutations of the gene encoding for the glucocerebrosidase (Sardi 
et al., 2017). Dysregulation of S1P signaling and of the metabolic 
machinery involved in the control of S1P levels has been largely 
demonstrated in neuroinflammatory and neurodegenerative 
TABLE 2 | Use of S1PR drugs in clinical trial for central nervous system (CNS) 
disease.
S1PR drugs in clinical 
trial
Target Indication for diseases
Fingolimod- FTY720 S1P1–S1P5 RR-MS
Siponimod- BAF312 S1P1, S1P5 SP-MS
RR-MS
Ozanimod- RPC1063 S1P1 RR-MS
Ceralifimod- ONO-4641 S1P1, S1P5 RR-MS
GSK2018682 S1P1 RR-MS
Ponesimod- ACT-128800 S1P1 RR-MS
KRP203 S1P1 Ulcerative colitis
Systemic lupus 
erythematosus
Cenerimod- ACT-33441 S1P1 Systemic lupus 
erythematosus
Amiselimod- MT1303 S1P1, S1P4, S1P5 RR-MS
Crohn’s disease
Psoriasis
Etrasimod- APD334 S1P1, S1P4, S1P5 Ulcerative colitis
RR-MS, relapsing–remitting multiple sclerosis; SP-MS, secondary progressive 
multiple sclerosis.
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diseases. The translational research in the field of S1P has been 
definitely more successful; in particular, addressing the family of 
S1P receptors as therapeutic target has led to the introduction of 
fingolimod for the therapy of RR-MS. Fingolimod is recognized 
as a very efficient drug in RR-MS, and pharmacological research 
in this sense has continued, leading to analogues with improved 
pharmacokinetic features and with a potential usefulness in the 
treatment of other forms of MS, where the neuroinflammation 
still is a major player. The complexity of fingolimod action in the 
brain suggests that this or similar drugs might be useful to treat 
CNS illnesses other than MS. Since discovery of fingolimod, new-
generation S1P receptor drugs are also being developed to target 
more specific S1P receptors. Overall, the family of S1PRs thus 
appears worthy of continued study and may provide significant 
therapeutic opportunities. Not only S1P receptors but also many 
of the enzymes involved in S1P metabolism bear the potential 
TABLE 3 | Research and clinical use of FTY720/fingolimod.
Disease Clinical trial In vitro (reference) In vivo (reference)
Amyotrophic lateral sclerosis Phase II Munoz-Saez et al., 2015 Potenza et al., 2016
Acute stroke Phase II Agudo-Lopez et al., 2010; Czubowicz et al., 
2015
Czech et al., 2009; Shichita et al., 2009; Zhou et al., 2010; Liesz 
et al., 2011; Wei et al., 2011; Wacker et al., 2012; Yung et al., 
2012; Liu et al., 2013a; Ichijo et al., 2015; Zheng et al., 2015
Schizophrenia Phase II Jang et al., 2011; Muhle et al., 2013
Rett syndrome Phase I Deogracias et al., 2012 Guy et al., 2001
Glioblastoma Phase I Paugh et al., 2009; Estrada-Bernal et al., 2012 Yoshida et al., 2010; Zhang et al., 2015
Alzheimer’s disease Puglielli et al., 2003 Asle-Rousta et al., 2013a; Hemmati et al., 2013; Asle-Rousta 
et al., 2014
Huntington’s disease Di Pardo et al., 2014; Miguez et al., 2015 Di Pardo et al., 2014
Parkinson’s disease Pyszko and Strosznajder, 2014b; Vargas-
Medrano et al., 2014
Komnig et al., 2018
Traumatic brain injury Zhang et al., 2007; Zhang et al., 2008; Mencl et al., 2014; 
Novgorodov et al., 2014
Epilepsy Hodgson et al., 1999; MacLennan et al., 2001; Mikati et al., 
2003; Akahoshi et al., 2011; Gao et al., 2012
Pain Chen et al., 2014 Coste et al., 2008; Doyle et al., 2011; Mair et al., 2011; Zhang 
et al., 2015
Krabbe’s disease O’sullivan and Dev, 2015 Contreras et al., 2010
FIGURE 5 | Novel modulators of S1P receptors.
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of promising therapeutic targets. From this point of view, in 
addition to the sphingosine kinases, the enzymes involved in 
the control of S1P levels along the catabolic pathways have been 
recently emerged as crucial in mediating the pathological role of 
S1P in brain disease. As an example, it is worth to remind that 
mutations in the S1P lyase are associated with neural toxicity 
(Choi and Saba, 2019). Thus, the array of possible druggable 
targets is considerably widening, and we would expect exciting 
developments in this field in the near future.
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